These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
110 related articles for article (PubMed ID: 15885322)
1. Evaluation of cerebrospinal fluid uPA, PAI-1, and soluble uPAR levels in HIV-infected patients. Sporer B; Koedel U; Popp B; Paul R; Pfister HW J Neuroimmunol; 2005 Jun; 163(1-2):190-4. PubMed ID: 15885322 [TBL] [Abstract][Full Text] [Related]
2. The urokinase receptor is overexpressed in the AIDS dementia complex and other neurological manifestations. Cinque P; Nebuloni M; Santovito ML; Price RW; Gisslen M; Hagberg L; Bestetti A; Vago G; Lazzarin A; Blasi F; Sidenius N Ann Neurol; 2004 May; 55(5):687-94. PubMed ID: 15122709 [TBL] [Abstract][Full Text] [Related]
3. Expression of the urokinase plasminogen activator and its receptor in HIV-1-associated central nervous system disease. Sidenius N; Nebuloni M; Sala S; Zerbi P; Price RW; Gisslen M; Hagberg L; Vago L; Lazzarin A; Blasi F; Cinque P J Neuroimmunol; 2004 Dec; 157(1-2):133-9. PubMed ID: 15579290 [TBL] [Abstract][Full Text] [Related]
4. [The plasma levels of urokinase plasminogen activator and urokinase plasminogen activator receptor and plasminogen activator inhibitor-1 in patients with different stages of liver cirrhosis following chronic hepatitis B]. Wu XR; Wang Q; Shi SS; Lu MH; Guo WD Zhonghua Gan Zang Bing Za Zhi; 2004 Feb; 12(2):82-4. PubMed ID: 14980106 [TBL] [Abstract][Full Text] [Related]
5. Measurement of plasminogen activator system components in plasma and tumor tissue extracts obtained from patients with breast cancer: an EORTC Receptor and Biomarker Group collaboration. Grebenchtchikov N; Maguire TM; Riisbro R; Geurts-Moespot A; O'Donovan N; Schmitt M; McGreal G; McDermott E; O'Higgins N; Brünner N; Sweep CG; Duffy MJ Oncol Rep; 2005 Jul; 14(1):235-9. PubMed ID: 15944795 [TBL] [Abstract][Full Text] [Related]
6. Role of the urokinase plasminogen activator system in patients with bacterial meningitis. Winkler F; Kastenbauer S; Koedel U; Pfister HW Neurology; 2002 Nov; 59(9):1350-5. PubMed ID: 12427882 [TBL] [Abstract][Full Text] [Related]
7. Deflazacort modulates the fibrinolytic pattern and reduces uPA-dependent chemioinvasion and proliferation in rheumatoid arthritis synoviocytes. Del Rosso A; Cinelli M; Guiducci S; Pignone A; Fibbi G; Margheri F; Gabrielli A; Giacomelli R; Coppini A; Del Rosso M; Matucci Cerinic M Rheumatology (Oxford); 2005 Oct; 44(10):1255-62. PubMed ID: 15998634 [TBL] [Abstract][Full Text] [Related]
8. Expression of urokinase-type plasminogen activator, urokinase-type plasminogen activator receptor and plasminogen activator inhibitors in patients with renal cell carcinoma: correlation with tumor associated macrophage and prognosis. Ohba K; Miyata Y; Kanda S; Koga S; Hayashi T; Kanetake H J Urol; 2005 Aug; 174(2):461-5. PubMed ID: 16006865 [TBL] [Abstract][Full Text] [Related]
9. The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion. Hildenbrand R; Schaaf A Int J Oncol; 2009 Jan; 34(1):15-23. PubMed ID: 19082473 [TBL] [Abstract][Full Text] [Related]
10. Reduced release of intact and cleaved urokinase receptor in stimulated whole-blood cultures from human immunodeficiency virus-1-infected patients. Ostrowski SR; Piironen T; Høyer-Hansen G; Gerstoft J; Pedersen BK; Ullum H Scand J Immunol; 2005 Apr; 61(4):347-56. PubMed ID: 15853918 [TBL] [Abstract][Full Text] [Related]
16. Effects of hypoxia and reoxygenation on the expression levels of the urokinase-type plasminogen activator, its inhibitor plasminogen activator inhibitor type-1 and the urokinase-type plasminogen activator receptor in human head and neck tumour cells. Sprague LD; Tomaso H; Mengele K; Schilling D; Bayer C; Stadler P; Schmitt M; Molls M Oncol Rep; 2007 May; 17(5):1259-68. PubMed ID: 17390074 [TBL] [Abstract][Full Text] [Related]
17. The role of urokinase-type plasminogen activator (uPA)/uPA receptor in HIV-1 infection. Alfano M; Sidenius N; Blasi F; Poli G J Leukoc Biol; 2003 Nov; 74(5):750-6. PubMed ID: 12960238 [TBL] [Abstract][Full Text] [Related]
19. Urokinase-type plasminogen activator system and breast cancer (Review). Han B; Nakamura M; Mori I; Nakamura Y; Kakudo K Oncol Rep; 2005 Jul; 14(1):105-12. PubMed ID: 15944776 [TBL] [Abstract][Full Text] [Related]
20. Inhibition of HIV replication by the plasminogen activator is dependent on vitronectin-mediated cell adhesion. Elia C; Cassol E; Sidenius N; Blasi F; Castagna A; Poli G; Alfano M J Leukoc Biol; 2007 Nov; 82(5):1212-20. PubMed ID: 17704294 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]